{"url_path":"/sec/cpix/8-k/2026-07-01/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","accession_number":"0001104659-26-079871","cik":"0001087294","ticker":"CPIX","issuer_name":"CUMBERLAND PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1087294/0001104659-26-079871-index.html","primary_entity_key":"0001087294","primary_entity_name":"CUMBERLAND PHARMACEUTICALS INC"},"word_count":461,"has_tables":true,"body_markdown":"false\n0001087294\n\n0001087294\n\n2026-06-29\n2026-06-29\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13\nOR 15(d) of The Securities Exchange Act of 1934**\n\n \n\nDate of Report (date of earliest\nevent reported): June 29, 2026\n\n \n\n**CUMBERLAND PHARMACEUTICALS INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Tennessee**\n**001-33637**\n**62-1765329**\n\n(State or other jurisdiction of incorporation)\n(Commission File Number)\n(I.R.S. Employer Identification No.)\n\n \n\n**1600 West End Avenue, Suite 1300 Nashville,\nTennessee 37203**\n\n(Address of Principal Executive Offices) (Zip Code)\n\n \n\n**(615) 255-0068**\n\nRegistrant's telephone number, including area code\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.\nbelow):\n\n \n\n¨ Written\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n¨ Soliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n¨ Pre-commencement\ncommunications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n¨ Pre-commencement\ncommunications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\nTrading Symbol(s)\nName of each exchange on which registered\n\nCommon Stock, no par value\nCPIX\nNASDAQ Global Select Market\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities\nExchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ¨\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\n \n\n \n\n \n\n**Introductory Note**\n\n \n\nThis\nCurrent Report on Form 8-K is being filed in connection with the closing on July 1, 2026 (the “**Closing Date**”) of the\npreviously announced strategic transaction (the “**Transaction**”) to integrate the\ncommercial products of Cumberland Pharmaceuticals Inc. (the “**Company**” or “**Cumberland**”) with the\nU.S. branded business of an affiliate of Apotex Inc., a corporation incorporated under the laws of the Province of Ontario (“**Apotex**”).\nThe Transaction was effected through the Asset Purchase Agreement (the “**Agreement**”), dated as of April 22, 2026, by\nand among Nuvo Pharmaceuticals (Ireland) DAC (“**Nuvo**”), Apotex and the Company, whereby Nuvo and certain affiliates\nof Apotex acquired the Company’s FDA-approved products, consisting of Acetadote®,\nCaldolor®, Kristalose®, Sancuso®,\nVaprisol®, Vibativ®, as well as\nthe Company’s certain product related equity interests (collectively, the “**Assets**”). Cumberland has retained\nthe assets associated with the Company’s ifetroban product candidates and Cumberland Emerging Technologies, Inc. (the “**Retained\nPrograms**”), which the Company intends to continue to develop."}